鎮痛薬の世界市場-2023-2030

市場概要

痛みは、組織の損傷や病気のために発現する厄介な感覚です。腹部潰瘍、硬化症、変形性関節症、慢性関節炎、糖尿病性神経障害、がんなど、様々な状態が苦痛を誘発する可能性があります。感覚痛は、痛みの持続時間から、長期的に続く慢性痛と、数ヶ月、数週間、数日と続く短期的な急性痛とに分けられます。一方、慢性痛は数年単位で持続します。

市場力学

患者のQOLを向上させるための鎮痛薬に対するニーズの高まりが、予測期間中の世界の鎮痛薬市場の成長を後押ししています。

鎮痛薬に対する需要の高まりが、世界の市場の成長を後押ししています。

鎮痛薬は、術後の痛み、深刻な身体的損傷、またはがんによる痛みなどの状況における極度の痛みを緩和します。また、その他の長期的な痛みにも使用されます。術後の痛み、身体的外傷、および関節炎や癌などの慢性非伝染性疾患の増加により、鎮痛薬の需要が高まっています。例えば、WHOによると、毎年数百万人以上が非致命的な怪我を負い、入院や一般開業医による治療、救急部や急性期病院を訪れることになり、しばしば一時的または永久的な障害に見舞われています。また、国際がん研究機関WHOは、2020年に世界で異なる種類のがんの新規症例が約1929万2789件発生したと評価しています。同様に、世界関節リウマチネットワークによると、2021年には約3億5000万人が関節炎を患って生活しているとされています。さらに、NIHは、手術を受けた患者の75％以上が術後の急性疼痛を経験し、その重症度は中程度から高い可能性があるとしています。

さらに、世界的に実施される手術の数が増加していることも、世界の鎮痛薬市場を拡大させています。例えば、European core health indicators（ECHI）によると、EUの病院で最も多く行われている手術・処置は、白内障手術と帝王切開の2つです。白内障手術は、2020年にEU加盟国全体で366万回実施されました。同時に、帝王切開術は2020年にEUで少なくとも112万回実施されました。

他の痛みを和らげる治療法の入手・導入が、市場の世界の成長における大きなハードルとなっています。

しかし、経皮的電気神経刺激（TENS）療法など、低電圧電流を使用して痛みを治療する他の鎮痛治療法の入手・導入が可能であることが挙げられます。さらに、2021年1月には、ボストン・サイエンティフィック社が、個別化された疼痛緩和のための治療選択を組み込んだ脊髄刺激装置（SCS）システムのポートフォリオであるWaveWriter Alphaを発表しています。

COVID-19の影響分析

COVID-19の大流行は、世界の鎮痛薬市場に大きな影響を与えています。コロナウイルス病2019（COVID-19）流行時の慢性疼痛管理は、特にCOVID-19感染が筋痛、参照痛、広範な痛覚過敏と関連しているという証明が高まっており、困難な状況でした。非オピオイド鎮痛薬は、マルチモーダル鎮痛の一部として軽度から中等度の痛みに対処する際に単独または非ステロイド性抗炎症薬（NSAIDs）と組み合わせて使用されるが、発熱、頭痛、急性または慢性痛などのCOVID-19の症状を緩和するために安全に利用され、鎮痛薬の需要増加につながり、市場の成長にプラスの影響を及ぼしました。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 鎮痛薬に対する需要の高まり
    • 老年人口の増加
  • 抑制要因
    • 他の選択肢の利用可能性
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 投与経路別

• 経口剤
• 注射剤
• 外用剤

第8章 タイプ別

• 急性期
• 慢性期

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第12章 企業プロファイル

• Teva Pharmaceutical Industries Ltd.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Bayer AG
• Sanofi S.A.
• GlaxoSmithKline plc.
• Bristo-Meyers Squibb and Company
• Mylan N.V.
• Merck & Co.
• Cardinal Health Inc.

第13章 DataM

Market Overview

The global pain relief medication size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Pain is a troubling sensation developed because of tissue injury or disease. Various conditions can induce distress, like abdominal ulcers, sclerosis, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Based on the duration of pain, sensation pain is of two types chronic, lasting for the long term, and acute pain for the short term, which can last for months, weeks, or days. In contrast, chronic pain lasts for years.

Market Dynamics

The rising need for pain-relieving medication to increase the patient quality of life is boosting the global pain-relief medication market growth during the forecast period.

The growing demand for pain-relieving medication is fueling the market growth globally.

Pain Relief Medications alleviate extreme pain in conditions such as post-surgery pain, a serious physical injury, or pain from cancer. They are also used for other types of long-standing pain. The growing number of postoperative pains, physical traumas and chronic non-communicable diseases such as arthritis and cancer are creating the demand for Pain Relief Medication. For instance, according to the WHO, more than millions suffer non-fatal injuries each year, which lead to hospitalizations or treatment by general practitioners or emergency department and acute care visits and often result in temporary or permanent disability. Also, the International Agency for Research on Cancer WHO assessed there were about 19292789 new cases of different types of cancer globally in 2020. Similarly, according to the Global Rheumatoid Arthritis Network, approximately 350 million people lived with arthritis in 2021. Additionally, the NIH states that over 75% of the patients who have undergone surgery experience acute postoperative pain, which might be medium to high in severity.

Furthermore, the increasing number of surgeries performed globally also expands the global pain relief medication market. For instance, according to the European core health indicators (ECHI), the two most common surgical operations and procedures performed in EU hospitals were cataract surgery and cesarean sections. Cataract surgery was conducted 3.66 million times in 2020 across the EU Member States. At the same time, the cesarean section procedure was performed at least 1.12 million times in the EU in 2020.

The availability and introduction of other pain-relieving treatments is a major hurdle in the market's global growth.

However, the availability and introduction of other pain relieving treatments, such as Transcutaneous Electrical Nerve Stimulation (TENS) therapy, involves using low-voltage electric currents to treat pain. Furthermore, in January 2021, Boston Scientific Corporation introduced the WaveWriter Alpha, a portfolio of Spinal Cord Stimulator (SCS) systems that incorporate treatment choices for personalized pain relief.

COVID-19 Impact Analysis

The COVID-19 pandemic has greatly impacted the global pain relief medication market. Chronic pain management during the coronavirus disease 2019 (COVID-19) pandemic was difficult, particularly with rising proof that COVID-19 infection is associated with myalgias, referred pain, and widespread hyperalgesia. Non-Opioid Analgesic medication used alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in addressing mild-to-moderate pain as part of multimodal analgesia, also be utilized safely to relieve symptoms of COVID-19, like fever, headache, and acute or chronic pain, which led to increased demand for pain relief medication and positively impacted the market growth.

Segment Analysis

The chronic pain type is predicted to hold a large share of the global pain relief medication market during the forecast period (2022-2029).

The chronic pain type is expected to hold most of the market share during the forecasted period. According to the Johns Hopkins Hospital, Chronic pain is long-standing pain that lasts beyond the normal healing period or surfaces along with a chronic health condition, like arthritis, Cancer pain, migraines, cluster headaches and others. Chronic pain may be "appearing" and "disappearing" or continuous. The U.S. spends $3.5 trillion annually on health care, with 90% of that going to chronic conditions, including chronic pain. Moreover, according to an article by The Lancet, Chronic pain exerts an immense individual and financial hindrance, impacting over 30% of individuals worldwide. Also, according to the NIH, Chronic pain is favorably dominant among geriatric adults, associated with substantial suffering, disability, social solitariness, and higher expenditures and burden to health care systems. Thus, the growing geriatric population is contributing to the growth of the chronic pain segment. For example, according to WHO, the geriatric population accounted for 1 billion in 2020 and is predicted to reach 1.4 billion by 2030. Thus the data mentioned above indicate that the chronic pain type will dominate the global pain relief medication market

Geographical Analysis

North America oppresses the global pain relief medication market throughout the forecast period (2022-2029).

Owing to the high number of chronic disease cases and the presence of key market players, the North American pain relief medication market is assessed to grow at a high CAGR in the forecast period (2022-2029). Such as, according to the American cancer society estimations, in 2022, about 1.9 million new cancer cases will be analyzed, and around 609,360 cancer-caused deaths in the United States. Likewise, CDC anticipated that approximately 78 million U.S. adults will live with doctor-diagnosed arthritis in 2040, increasing the demand for the Pain Relief Medication analgesic. Similarly, the major key players holding a larger share of the market are U.S. based, such as Johnson & Johnson, Pfizer Inc., Purdue Pharma, Endo International, Mylan, Impax Laboratories and Indivior, contributing to the dominance of North America over the global Pain Relief Medication market. Therefore from the data mentioned above, it is anticipated that North America will hold most of the global pain relief medication market throughout the forecasted period (2022-2029).

Competitive Landscape

The pain relief medication market is moderately competitive since there is a growing demand for pain relief medication and local and global key players. Some key players are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. These key players hold the market through acquisition, product launches, and collaborations. For instance, in July 2021, Venus Remedies Limited launched a consumer healthcare division that will offer various products for pain management.

Teva Pharmaceutical Industries Ltd.

Overview

Teva Pharmaceuticals was founded in 1901 in Jerusalem. It is today among the top 15 pharmaceutical companies worldwide. Teva has over 3600 medicines in its product portfolio, with 37,000 employees working globally and 53 production sites globally.

Product Portfolio:

Teva Pharmaceutical's product portfolio of pain relief medication has: Hydromorphone comes under the family of drugs known as opioid painkillers. It is employed to treat moderate-to-severe pain, such as pain after surgery.

The global pain relief medication market report would provide access to approximately 40 + market data tables, 45 + figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Growing Demand for Pain Relief Medication
    • 4.1.1.2. Growing Geriatric Population
  • 4.1.2. Restraints
    • 4.1.2.1. Availability of Other Options
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Injectable
• 7.4. Topical

8. By Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 8.1.2. Market Attractiveness Index, By Type
• 8.2. Acute
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Chronic

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacy
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Retail Pharmacy
• 9.4. Online Pharmacy

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Company Profiles

• 12.1. Teva Pharmaceutical Industries Ltd.
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Pfizer Inc.
• 12.3. Johnson & Johnson Services Inc.
• 12.4. Bayer AG
• 12.5. Sanofi S.A.
• 12.6. GlaxoSmithKline plc.
• 12.7. Bristo-Meyers Squibb and Company
• 12.8. Mylan N.V.
• 12.9. Merck & Co.
• 12.10. Cardinal Health Inc.

LIST NOT EXHAUSTIVE

13. DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us